var data={"title":"Leflunomide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Leflunomide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6440?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=leflunomide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Leflunomide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709008\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Embryofetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide is contraindicated in pregnant women because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals administered leflunomide at doses lower than the human exposure level. Exclude pregnancy before the start of treatment with leflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during leflunomide treatment and during an accelerated elimination procedure after leflunomide treatment. Stop leflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Concomitant use of leflunomide with other potentially hepatotoxic drugs may increase the risk of liver injury. Patients with preexisting acute or chronic liver disease, or those with ALT more than twice the upper limit of normal (ULN) before initiating treatment, are at increased risk and should not be treated with leflunomide. Monitor ALT levels at least monthly for 6 months after starting leflunomide, and thereafter every 6 to 8 weeks. If leflunomide-induced liver injury is suspected, stop leflunomide treatment, start an accelerated drug elimination procedure, and monitor liver tests weekly until normalized.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187136\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Arava</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187137\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Leflunomide;</li>\n      <li>Arava;</li>\n      <li>Mylan-Leflunomide;</li>\n      <li>PHL-Leflunomide;</li>\n      <li>PMS-Leflunomide;</li>\n      <li>Sandoz-Leflunomide;</li>\n      <li>Teva-Leflunomide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187163\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187140\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Rheumatoid arthritis:</b> Oral: Loading dose: 100 mg once daily for 3 days; maintenance dose: 20 mg once daily, may reduce dose to 10 mg once daily if higher dose is not tolerated (maximum dose: 20 mg once daily). <b>Note:</b> The loading dose may be omitted in patients at increased risk of hepatic or hematologic toxicity (eg, recent concomitant methotrexate or other immunosuppressive agents). Due to the long half-life of the active metabolite, serum concentrations may require a prolonged period to decline after dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>CMV disease, resistant to standard antivirals (off-label use):</b> Oral: Some authors recommend 100 to 200 mg/day for 5 to 7 days, followed by 40 to 60 mg/day (Avery 2004; Avery 2010). Others have utilized the standard rheumatoid arthritis dosing (John 2004). Adjust dose based on serum concentrations of metabolite and adverse events (Avery 2008; Avery 2010; Williams 2002). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595485\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile idiopathic arthritis (off-label use)</b> (Silverman 2005): Children &ge;3 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;20 kg: 100 mg as a single dose followed by 10 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 kg to 40 kg: 100 mg once daily for 2 days followed by 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;40 kg: 100 mg once daily for 3 days followed by 20 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187141\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187142\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187143\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Not recommended for use in patients with preexisting liver disease or those with baseline ALT &gt;2 times ULN; monitor liver function closely. Use is contraindicated in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187164\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>US labeling:</i> ALT elevations &gt;3 x ULN: Discontinue drug therapy and investigate probable cause; if leflunomide-induced, initiate accelerated drug elimination process and monitor liver tests weekly until normalized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ALT elevations 2 to 3 x ULN: May reduce maintenance dose to 10 mg once daily; monitor ALT weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Persistent ALT elevations &gt;2 x ULN or ALT elevations &gt;3 x ULN: Discontinue treatment and initiate drug elimination procedures. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Drug elimination procedure:</b> To achieve nondetectable serum concentrations (&lt;0.02 mg/L) of the active metabolite (teriflunomide) administer the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cholestyramine: 8 g 3 times daily for 11 days. If plasma concentrations are still high, additional cholestyramine treatment may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Activated charcoal: 50 g (made into suspension) every 12 hours for 11 days. If plasma concentrations are still high, additional activated charcoal treatment may be considered. Note: As an alternative, the Canadian labeling recommends activated charcoal 50 g 4 times daily for 11 days (may modify duration based on clinical response or laboratory results).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187114\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arava: 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187099\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9525956\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104525\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187115\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Rheumatoid arthritis:</b> Treatment of adults with active rheumatoid arthritis (RA).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726721\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Juvenile idiopathic arthritis; Acute and chronic rejection in recipients of solid organ transplants (prevention); Cytomegalovirus (CMV) disease in transplant recipients resistant to standard antivirals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16330214\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Leflunomide may be confused with lenalidomide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187106\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (9% to 17%), skin rash (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (17% to 27%), nausea (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (9% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (4% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal pain (5% to 8%), abdominal pain (5% to 6%), oral mucosa ulcer (3% to 5%), vomiting (3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (5% to 10%), increased serum ALT (&gt;3 x ULN: 2% to 4%; reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5% to 8%), weakness (3% to 6%), tenosynovitis (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (5% to 8%), rhinitis (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, increased blood pressure, leg thrombophlebitis, palpitations, varicose veins</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, enlargement of salivary glands, flatulence, sore throat, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukocytosis, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia, increased serum alkaline phosphatase, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, eye disease, papilledema, retinal hemorrhage, retinopathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea, flu-like symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Agranulocytosis, angioedema, cholestasis, colitis (including microscopic colitis), cutaneous lupus erythematosus, DRESS syndrome, erythema multiforme, exacerbation of psoriasis, hepatitis, hepatotoxicity (rare, including hepatic necrosis and hepatic failure), interstitial pneumonitis, interstitial pulmonary disease, jaundice, leukopenia, necrotizing angiitis (cutaneous), neutropenia, opportunistic infection, pancreatitis, pancytopenia, peripheral neuropathy, pulmonary fibrosis, pulmonary hypertension, pustular psoriasis, sepsis (including <i>Pneumocystis jirovecii</i> pneumonia and aspergillosis), severe infection, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187118\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to leflunomide or any component of the formulation; severe hepatic impairment; concomitant treatment with teriflunomide; pregnant women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to teriflunomide; moderate to severe renal impairment; immunodeficiency states; impaired bone marrow function or significant anemia, leukopenia, neutropenia, or thrombocytopenia due to causes other than rheumatoid arthritis; serious infections; impaired liver function; severe hypoproteinemia; women of childbearing potential who are not using reliable contraception before, during, and for a period of 2 years after treatment with leflunomide (or as long as plasma levels of the active metabolite are above 0.02 mg/L); breast-feeding; patients younger than 18 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187103\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Rare cases of dermatologic reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported; discontinue if evidence of severe dermatologic reaction occurs, and begin accelerated drug elimination procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Severe liver injury, including fatal liver failure, has been reported in some patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Concomitant use of leflunomide with other potentially hepatotoxic drugs may increase the risk of liver injury. Patients with preexisting acute or chronic liver disease, or those with ALT more than twice the upper limit of normal (ULN) before initiating treatment, are at increased risk and should not be treated with leflunomide. Monitor ALT levels at least monthly for 6 months after starting leflunomide, and thereafter every 6 to 8 weeks.</b> If ALT elevation &gt;3-fold the ULN occurs, interrupt therapy and investigate the cause. <b>If leflunomide-induced liver injury is suspected, stop leflunomide treatment, start an accelerated drug elimination procedure, and monitor liver tests weekly until normalized.</b> If leflunomide-induced liver injury is unlikely because another cause has been found, resumption of leflunomide therapy may be considered. If given concomitantly with methotrexate, follow the American College of Rheumatology (ACR) guidelines for monitoring methotrexate liver toxicity with ALT, AST, and serum albumin testing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicities: Pancytopenia, agranulocytosis, and thrombocytopenia have been reported with leflunomide therapy alone; most frequently hematologic toxicity occurs in patients receiving concomitant therapy with methotrexate or other immunosuppressive agents, or who had recently discontinued these therapies. In some cases, patients had a history of a significant hematologic abnormality. All patients should have platelet, white blood cell count (WBC), and hemoglobin or hematocrit monitored at baseline and monthly for 6 months following therapy initiation and then every 6 to 8 weeks thereafter. If used with concomitant methotrexate or other potential immunosuppressive agents, increase chronic monitoring to monthly. If evidence of bone marrow suppression occurs, stop treatment and initiate an accelerated drug elimination procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Blood pressure elevations have been observed; assess blood pressure at baseline and monitor periodically during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: May increase susceptibility to infection, including opportunistic pathogens (especially <i>Pneumocystis jirovecii</i> pneumonia, tuberculosis [including extrapulmonary tuberculosis], and aspergillosis). Severe infections, sepsis, and fatalities have been reported. Not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections. Caution should be exercised when considering the use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with chronic, latent, or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely; consider interrupting therapy and initiating accelerated drug elimination procedures if infection is serious.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial lung disease: Use has been associated with interstitial lung disease and worsening of preexisting interstitial lung disease (with some fatalities reported). The risk is increased in patients with a history of interstitial lung disease. Further investigate etiology in patients who develop new-onset or worsening of pulmonary symptoms (eg, cough and dyspnea, with or without associated fever). Accelerated drug elimination procedures should be considered if leflunomide is discontinued due to interstitial lung disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Use of some immunosuppressive medications may increase the risk of malignancies, especially lymphoproliferative disorders; impact of leflunomide on the development and course of malignancies is not fully defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Cases of peripheral neuropathy have been reported; most patients recover after treatment discontinuation, but symptoms may persist in some patients. Use with caution in patients &gt;60 years of age, receiving concomitant neurotoxic medications or patients with diabetes; discontinue if evidence of peripheral neuropathy occurs and begin accelerated drug elimination procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic disorders: Use with caution in patients with a history of significant hematologic abnormalities; avoid use with bone marrow dysplasia. The Canadian labeling contraindicates use with impaired bone marrow function or significant anemia, leukopenia, neutropenia, or thrombocytopenia due to causes other than rheumatoid arthritis. Use has been associated with rare pancytopenia, agranulocytosis, and thrombocytopenia, generally when given concurrently or recently with methotrexate or other immunosuppressive agents. Monitoring of hematologic function is required; discontinue if evidence of bone marrow suppression and begin accelerated drug elimination procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is not recommended due to risk of increased hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. The Canadian labeling contraindicates use in moderate to severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Safety has not been established in patients with latent tuberculosis infection. Patients should be screened for tuberculosis and if necessary, treated prior to initiating leflunomide therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppressants: If coadministered with other potential immunosuppressive agents, increased monitoring for hematological adverse effects is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: No clinical data are available on the efficacy and safety of vaccinations during leflunomide treatment. Vaccination with live vaccines is not recommended; consider the long elimination half-life of the leflunomide active metabolite (eg, teriflunomide) when considering live vaccine administration after leflunomide discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women of reproductive potential: <b>[US Boxed Warning]: Leflunomide is contraindicated in pregnant women because of the potential for fetal harm. Adverse events were observed in animal reproduction studies with doses lower than the expected human exposure. Exclude pregnancy before the start of treatment in females of reproductive potential. Advise females of reproductive potential to use effective contraception during treatment and during an accelerated elimination procedure after treatment is discontinued. Discontinue therapy and use an accelerated elimination procedure if pregnancy occurs during treatment.</b> Women of reproductive potential should also undergo drug elimination procedures following therapy discontinuation. The Canadian labeling contraindicates use in women of childbearing potential who are not using reliable contraception before, during, and for a period of 2 years after treatment with leflunomide (or as long as plasma levels of the active metabolite are above 0.02 mg/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug elimination procedure: Due to variations in clearance, it may take up to 2 years to reach low levels of leflunomide metabolite (eg, teriflunomide) serum concentrations. An accelerated drug elimination procedure using cholestyramine or activated charcoal is recommended when a more rapid elimination is needed (eg, severe adverse reaction, suspected hypersensitivity or pregnancy). Refer to dosing for detailed accelerated elimination procedure. Verify plasma teriflunomide concentrations are less than 0.02 mg/L by tests at least 14 days apart. If concentrations are greater than 0.02 mg/L, repeat the accelerated elimination procedure. Use of accelerated drug elimination may potentially result in return of disease activity if the patient has been responding to leflunomide treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187157\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C8 (moderate), CYP2C9 (weak); <b>Induces</b> CYP1A2 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187108\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10097&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bendamustine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease serum concentrations of the active metabolite(s) of Leflunomide. Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Charcoal, Activated: May decrease serum concentrations of the active metabolite(s) of Leflunomide. Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to charcoal when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inducers may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inducers): CYP1A2 Inducers (Moderate) may decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Substrates (High risk with Inhibitors): CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Leflunomide may decrease the serum concentration of Erlotinib.  Management: Avoid the concomitant use of erlotinib and leflunomide if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Leflunomide. Particular concerns are an increased risk of pancytopenia and/or hepatotoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pirfenidone: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Pirfenidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Leflunomide may increase the serum concentration of Repaglinide. Specifically, the active metabolite of leflunomide may increase repaglinide concentrations. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May increase serum concentrations of the active metabolite(s) of Leflunomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riluzole: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Riluzole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Selexipag.  Management: If initiating selexipag in a patient on a moderate CYP2C8 inhibitor, consider a less frequent dosing regimen (ie, once daily). If initiating a moderate CYP2C8 inhibitor in a patient on selexipag, consider a selexipag dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: Leflunomide may enhance the adverse/toxic effect of Teriflunomide. Leflunomide may increase the serum concentration of Teriflunomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TOLBUTamide: Leflunomide may increase the serum concentration of TOLBUTamide. Specifically, the active metabolite of leflunomide (teriflunomide) may both increase total tolbutamide concentrations and increase the free fraction (i.e., non-protein bound) of tolbutamide. TOLBUTamide may increase the serum concentration of Leflunomide. Specifically, tolbutamide may increase the proportion of non-protein-bound (i.e., free fraction) teriflunomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Leflunomide may enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live).  Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Leflunomide may enhance the anticoagulant effect of Vitamin K Antagonists. Leflunomide may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187132\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">No interactions with food have been noted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187121\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Leflunomide is contraindicated in pregnant women because of the potential for fetal harm. Adverse events were observed in animal reproduction studies with doses lower than the expected human exposure. Exclude pregnancy before the start of treatment in females of reproductive potential. Advise females of reproductive potential to use effective contraception during treatment and during an accelerated elimination procedure after treatment is discontinued. Discontinue therapy and use an accelerated elimination procedure if pregnancy occurs during treatment.</b> Women of reproductive potential should not receive therapy until pregnancy has been excluded, they have been counseled concerning fetal risk, and reliable contraceptive measures have been confirmed. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) are verified. This may be accomplished by the use of an enhanced drug elimination procedure using cholestyramine. Serum concentrations &lt;0.02 mg/L should be verified by 2 separate tests performed at least 14 days apart. If serum concentrations are &gt;0.02 mg/L, additional cholestyramine treatment should be considered. As an alternative to cholestyramine, the Canadian labeling recommends that activated charcoal may be used to enhance drug elimination. </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">It is not known if males taking leflunomide may contribute to fetal toxicity. Males taking leflunomide who wish to father a child should consider discontinuing therapy and using the cholestyramine procedure to eliminate the medication. The Canadian labeling recommends avoiding use in males capable of fathering a child and who are not using reliable contraception during and for a total of 2 years after treatment unless an elimination procedure is used; for men receiving treatment and desiring to father a child, serum concentrations of the active metabolite should be verified by 2 separate tests performed at least 14 days apart. If levels &lt;0.02 mg/L are confirmed with the second test, an additional waiting period of 3 months is recommended.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to leflunomide during pregnancy in the Pregnancy Registry (877-311-8972 or http://www.pregnancystudies.org/participate-ina-study/).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187122\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known whether leflunomide is secreted in human milk. Because the potential for serious adverse reactions exists in breast-feeding infants, a decision should be made whether to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother. Canadian labeling contraindicates use in breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187112\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rheumatoid arthritis:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Pregnancy test to rule out pregnancy prior to initiating therapy; baseline evaluation for active tuberculosis and screen patients for latent tuberculosis; blood pressure (baseline and periodically thereafter); signs/symptoms of severe infection or pulmonary symptoms (eg, cough, dyspnea); complete blood count (WBC, platelet count, hemoglobin or hematocrit) at baseline and monthly during the initial 6 months of treatment; if stable, monitoring frequency may be decreased to every 6 to 8 weeks thereafter (continue monthly when used in combination with other immunosuppressive agents [eg, methotrexate]); hepatic function (transaminases) at least monthly for the first 6 months of treatment, then every 6 to 8 weeks thereafter (discontinue if ALT &gt;3 x ULN, treat with accelerated elimination procedure, and monitor liver function at least weekly until normal).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: Complete blood counts, serum creatinine, serum transaminases: Baseline and every 2 to 4 weeks during the initial 3 months after initiation or following dose increases, then every 8 to 12 weeks during 3 to 6 months of treatment, followed by every 12 weeks beyond 6 months of treatment; monitor more frequently if clinically indicated (Singh [ACR 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CMV disease (off-label use): Monitor serum trough concentrations of active metabolite (also see Reference Range).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11394964\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">CMV disease:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Initial: Obtain 24 hours after last dose of loading regimen and periodically thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic concentration: Active metabolite (teriflunomide): Trough: 50 to 80 mcg/mL (Avery 2010) or up to 100 mcg/mL (Williams 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187102\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Leflunomide is an immunomodulatory agent that inhibits pyrimidine synthesis, resulting in antiproliferative and anti-inflammatory effects. Leflunomide is a prodrug; the active metabolite is responsible for activity. For CMV, may interfere with virion assembly. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187117\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Teriflunomide: 11 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Teriflunomide: &gt;99% to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to an active metabolite teriflunomide, which accounts for nearly all pharmacologic activity; further metabolism to multiple inactive metabolites; undergoes enterohepatic recirculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Teriflunomide: Mean: 18 to 19 days; enterohepatic recycling appears to contribute to the long half-life of this agent, since activated charcoal and cholestyramine substantially reduce plasma half-life </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Teriflunomide: 6 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (37.5%); urine (22.6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187120\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Arava Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1,407.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,407.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Leflunomide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $229.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $237.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187124\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Airuohua (CN);</li>\n      <li>Arabloc (AU, NZ);</li>\n      <li>Arastad (VN);</li>\n      <li>Arava (AE, AR, AT, AU, BB, BD, BE, BG, BH, BO, BR, BS, CH, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TT, TW, VE, VN);</li>\n      <li>Aravida (PE);</li>\n      <li>Arheuma (TW);</li>\n      <li>Arolef (BD);</li>\n      <li>Arresto (LK);</li>\n      <li>Artrilab (CL);</li>\n      <li>Cartina (LK);</li>\n      <li>Imaxetil (PY);</li>\n      <li>Inflaxen (CO);</li>\n      <li>Kinetos (UY);</li>\n      <li>Leflu (BD);</li>\n      <li>Lefluar (AR);</li>\n      <li>Lefluartil (ES);</li>\n      <li>Leflyutab (UA);</li>\n      <li>Lefno (UA);</li>\n      <li>Lefora (LK);</li>\n      <li>Lefra-20 (ZW);</li>\n      <li>Motoral (BD);</li>\n      <li>Movelef (LK);</li>\n      <li>Nodia (BD);</li>\n      <li>R-A (KR);</li>\n      <li>Repso (IE, MT);</li>\n      <li>Rheufact (QA);</li>\n      <li>Rheumide (KR);</li>\n      <li>Rualba (KR);</li>\n      <li>Synomid (BD);</li>\n      <li>Youtong (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arava (leflunomide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arava (leflunomide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avery RK, Bolwell BJ, Yen-Lieberman B, et al, &ldquo;Use of Leflunomide in an Allogenic Bone Marrow Transplant Recipient With Refractory Cytomegalovirus Infection,&rdquo; <i>Bone Marrow Transplant</i>, 2004, 34(12):1071-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avery RK, Mossad SB, Poggio E, et al, &ldquo;Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes,&rdquo; <i>Transplantation</i>, 2010, 90(4):419-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/20683281/pubmed\" target=\"_blank\" id=\"20683281\">20683281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avery RK, &ldquo;Update in Management of Ganciclovir-Resistant Cytomegalovirus Infection,&rdquo; <i>Curr Opin Infect Dis</i>, 2008, 21(4):433-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/18594298/pubmed\" target=\"_blank\" id=\"18594298\">18594298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20472925\"></a>Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. <i>J Rheumatol</i>. 2010;37(8):1763-1767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/20472925/pubmed\" target=\"_blank\" id=\"20472925\">20472925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox RI, &ldquo;Mechanism of Action of Leflunomide in Rheumatoid Arthritis,&rdquo; <i>J Rheumatol</i>, 1998, 53:20-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23024081\"></a>Jahan A, Dewan V, Pal Yadav TP. Leflunomide in systemic onset Juvenile idiopathic arthritis. <i>Indian Pediatr</i>. 2012;49(9):750-752.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/23024081/pubmed\" target=\"_blank\" id=\"23024081\">23024081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    John GT, Manivannan J, Chandy S, et al, &ldquo;Leflunomide Therapy for Cytomegalovirus Disease in Renal Allograft Recipients,&rdquo; <i>Transplantation</i>, 2004, 77(9):1460-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/15167608/pubmed\" target=\"_blank\" id=\"15167608\">15167608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;New Drugs for Rheumatoid Arthritis,&rdquo; <i>Med Lett Drugs Ther</i>, 1998, 40(1040):110-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/9844625/pubmed\" target=\"_blank\" id=\"9844625\">9844625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Popovic M, Stefanovic D, Pejnovic N, et al, &ldquo;Comparative Study of the Clinical Efficacy of Four DMARDs (Leflunomide, Methotrexate, Cyclosporine, and Levamisole) in Patients With Rheumatoid Arthritis,&rdquo; <i>Transplant Proc</i>, 1998, 30(8):4135-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/9865325/pubmed\" target=\"_blank\" id=\"9865325\">9865325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rozman B, &ldquo;Clinical Experience With Leflunomide in Rheumatoid Arthritis,&rdquo; <i>J Rheumatol</i>, 1998, 53:27-32.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15843668\"></a>Silverman E, Mouy R, Spiegel L, et al; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. <i>N Engl J Med</i>. 2005;352(16):1655-1666.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/15843668/pubmed\" target=\"_blank\" id=\"15843668\">15843668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Rheumatol</i>. 2016;68(1):1-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/26545940/pubmed\" target=\"_blank\" id=\"26545940\">26545940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smolen JS, Kalden JR, Scott DL, et al, &ldquo;Efficacy and Safety of Leflunomide Compared With Placebo and Sulfasalazine in Active Rheumatoid Arthritis: A Double-Blind, Ramdomised, Multicentre Trial,&rdquo; <i>Lancet</i>, 1999, 353(9149):259-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/9929017/pubmed\" target=\"_blank\" id=\"9929017\">9929017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams JW, Mital D, Chong A, et al, &quot;Experiences With Leflunomide in Solid Organ Transplantation,&quot; <i>Transplantation</i>, 2002, 73(3):358-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leflunomide-drug-information/abstract-text/11884931/pubmed\" target=\"_blank\" id=\"11884931\">11884931</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10097 Version 164.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709008\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187136\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187137\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F187163\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187140\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26595485\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F187141\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F187142\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F187143\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F187164\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187114\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F187099\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9525956\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104525\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F187115\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726721\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16330214\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187106\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187118\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187103\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F187157\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187108\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F187132\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187121\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F187122\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F187112\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F11394964\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187102\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F187117\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187120\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187124\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10097|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=leflunomide-patient-drug-information\" class=\"drug drug_patient\">Leflunomide: Patient drug information</a></li></ul></div></div>","javascript":null}